Immunosin (Aminosyn II) is NOT indicated for COVID-19 treatment or prevention
Immunosin (Aminosyn II) is an intravenous amino acid solution used for nutritional support in patients who cannot receive adequate oral nutrition—it has no role in treating or preventing COVID-19 infection. 1
What Immunosin Actually Is
Immunosin (Aminosyn II) is FDA-approved exclusively as a source of nitrogen for parenteral nutrition. It is administered either:
- Peripherally with dilute dextrose (5-10%) for short-term nutritional support
- Centrally via superior vena cava catheter for patients requiring total parenteral nutrition (TPN)
The FDA labeling makes no mention of antiviral, immunomodulatory, or COVID-19 treatment properties 1.
Confusion with Inosine Pranobex
You may be confusing "Immunosin" with inosine pranobex (IP), which is a completely different medication. Inosine pranobex is an immunomodulatory agent that showed efficacy in a 2022 phase 3 randomized controlled trial for mild to moderate COVID-19. In this study of 416 patients, IP demonstrated:
- Significantly higher clinical response and cure rates by Day 6
- Earlier clinical recovery
- Fewer adverse events
- No mortality
The study concluded IP should be started early in mild to moderate COVID-19 to maximize benefit 2.
Current COVID-19 Treatment Guidelines
For actual COVID-19 treatment, follow evidence-based guidelines:
- Mild to moderate COVID-19 in adults: Use nirmatrelvir/ritonavir, remdesivir, or molnupiravir as recommended by the 2025 IDSA guidelines 3
- Severe/critical hospitalized COVID-19: Consider infliximab per 2025 IDSA guidance 4
- Immunocompromised patients: Follow specialized management protocols outlined in the 2025 ESCMID consensus document 5
Critical Caveat
Do not use Aminosyn II (Immunosin) for COVID-19. It is a nutritional supplement with significant risks when administered centrally (pneumothorax, sepsis, metabolic complications) and requires specialized expertise for safe administration 1. Using it for COVID-19 would be off-label, unsupported by evidence, and potentially harmful.
If you are seeking inosine pranobex specifically, note that while it showed promise in 2022 trials 2, it is not included in major 2025 COVID-19 treatment guidelines 3, 4, 5, suggesting other antivirals have superseded it as preferred options.